August 10, 2016
Otsuka Holdings has begun a PII study in Japan for its investigational Duchenne muscular dystrophy (DMD) treatment TAS-205, the company said in its R&D update on August 9. TAS-205 is a selective hematopoietic prostaglandin D synthase (HPGDS) inhibitor. It is...read more